Recombinant Treponema pallidum/TP TPP47 Protein, C-His

Introduction
Recombinant proteins have become an essential tool in the field of biotechnology and medicine. These proteins are produced by manipulating the genetic material of an organism to express a desired protein. One such protein is the Recombinant Treponema pallidum/TP TPP47 protein, which has gained significant attention in the scientific community due to its potential applications in the diagnosis and treatment of syphilis.

Structure of Recombinant Treponema pallidum/TP TPP47 Protein
The TP TPP47 protein is a surface-exposed lipoprotein found in the outer membrane of the bacterium Treponema pallidum, the causative agent of syphilis. The recombinant version of this protein is produced by cloning the gene encoding TP TPP47 into a suitable expression vector and expressing it in a host organism, such as Escherichia coli.

The TP TPP47 protein has a molecular weight of approximately 47 kDa and contains 431 amino acids. It has a unique structure consisting of four domains: a signal peptide, a lipoprotein signal peptide, a lipoprotein lipid attachment site, and a C-terminal domain. The C-terminal domain is the most conserved region of the protein and contains the antigenic epitopes that are essential for its diagnostic and therapeutic applications.

Activity of Recombinant Treponema pallidum/TP TPP47 Protein
The TP TPP47 protein is a major virulence factor of Treponema pallidum and plays a crucial role in the pathogenesis of syphilis. It is involved in the attachment and invasion of host cells, as well as the evasion of the host immune response. The recombinant version of this protein retains its biological activity and has been extensively studied for its potential diagnostic and therapeutic applications.

One of the key activities of the TP TPP47 protein is its ability to elicit a strong immune response in infected individuals. This makes it an attractive candidate for the development of diagnostic tests for syphilis. Several studies have shown that the recombinant TP TPP47 protein can be used as an antigen in various serological tests, such as enzyme-linked immunosorbent assay (ELISA) and Western blot, for the detection of antibodies against Treponema pallidum.

Application of Recombinant Treponema pallidum/TP TPP47 Protein
The recombinant TP TPP47 protein has a wide range of applications in the diagnosis and treatment of syphilis. Its ability to elicit a strong immune response and the presence of highly conserved antigenic epitopes make it a promising candidate for the development of more accurate and sensitive diagnostic tests for syphilis.

In addition to its diagnostic potential, the recombinant TP TPP47 protein also has therapeutic applications. Studies have shown that this protein can be used as a vaccine candidate for the prevention of syphilis. By inducing a strong immune response, the vaccine can protect individuals from acquiring the infection and potentially decrease the spread of the disease.

Furthermore, the TP TPP47 protein has also been studied for its potential as a therapeutic target for the treatment of syphilis. It has been shown to be essential for the survival and virulence of Treponema pallidum, making it a promising target for the development of novel antibiotics.

Conclusion
In conclusion, the Recombinant Treponema pallidum/TP TPP47 protein is a crucial virulence factor of the bacterium Treponema pallidum and has a unique structure and biological activity. Its potential applications in the diagnosis and treatment of syphilis make it a valuable tool in the fight against this sexually transmitted infection. Further research and development of this protein may lead to more accurate diagnostic tests and effective treatments for syphilis.

ProteoGenix catalogue number ARO-P12735. For research use only.

Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 47.48 kDa; Fragment: Cys20-Gln434; Buffer: 0.01M PBS, pH 7.4..

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet